Autologous umbilical cord blood mononuclear cell therapy for hypoplastic left heart syndrome: a nonrandomized control trial of the efficacy and safety of intramyocardial injections

Table 4 Serious adverse events, comparison by group

	Treatment group (n = 50)	Control group (n = 45)	P value
Did the subject have at least one SAE within 1- month of enrollment?			0.0568*
Yes	24 (48.0%)	13 (28.9%)
No	26 (52.0%)	32 (71.1%)
Did the subject have at least one SAE within 3- months of enrollment?			0.048*
Yes	29 (58.0%)	17 (37.8%)
No	21 (42.0%)	28 (62.2%)
Did the subject have at least one SAE within 12- months of enrollment?			0.143*
Yes	34 (68.0%)	24 (53.3%)
No	16 (32.0%)	21 (46.7%)
SAE: Serious adverse event *Chi-Square p value.

ISSN: 1757-6512